With a 5-year average dividend growth rate of 13.68%, McKesson Corporation (NYSE:MCK) is included among the 14 Best Dividend Stocks to Buy for Steady Growth.
On May 9, UBS analyst Kevin Caliendo raised the firm’s price recommendation on McKesson Corporation (NYSE:MCK) to $1,050 from $1,000. It reiterated a Buy rating on the shares. The analyst said that despite what he described as a “messy” Q4 print, the company’s initial FY27 outlook appeared “good enough,” according to a research note shared with investors.
On May 8, BofA analyst Allen Lutz lowered the firm’s price goal on McKesson to $900 from $1,000. It maintained a Buy rating on the stock. Lutz said McKesson reported “a mixed quarter,” though its FY27 guidance and reaffirmed long-range plan were viewed as positive developments. The analyst added that the lower price target reflected multiple contractions across peers.
During its fiscal Q4 2026 earnings call, Brian Tyler said the company delivered 18% growth in adjusted earnings per diluted share for fiscal 2026. He also noted that operating cash flow reached $6.2 billion, surpassing internal expectations, while McKesson returned $5.1 billion to shareholders. Tyler highlighted continued strength in specialty medications, saying the company added more than 570 providers during fiscal 2026. He also said Ambient Scribe technology is now being used by more than 1,900 providers.
Discussing patient support efforts, Tyler said the company recorded its strongest season so far by supporting a record 3.4 million patients. He also pointed to the recent launch of what he described as an industry-first integrated specialty access and affordability solution designed to reduce fragmentation that can delay treatment starts.
McKesson Corporation (NYSE:MCK) is a diversified healthcare services company focused on improving health outcomes for patients. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical products and other healthcare-related items across the United States.
While we acknowledge the risk and potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MCK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Inflation-Hedge Stocks to Buy for 2026 and 10 Best Stocks to Buy to Beat the S&P 500
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center